In Silico and In Vitro anticancer activity of isolated novel marker compound from chemically modified bioactive fraction from Curcuma longa (NCCL)

Arshi Naqvi; Richa Malasoni; Swati Gupta; Akansha Srivastava; Rishi R Pandey; Anil Kumar Dwivedi

Articles

Abstract

Pharmacognosy Magazine,2017,13,51s,s640-s644.

DOI:10.4103/pm.pm_23_17

Published:October 2017

Type:Original Article

Authors:

Author(s) affiliations:

Arshi Naqvi¹, Richa Malasoni², Swati Gupta², Akansha Srivastava², Rishi R Pandey², Anil Kumar Dwivedi²
¹Department of Chemistry, Faculty of Science, Taibah University, Al-Madina Al-Munawwara, Kingdom of Saudi Arabia; Division of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
²Division of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India

Abstract:

Background: Turmeric (Curcuma longa) is reported to possess wide array of biological activities. Herbal Medicament (HM) is a standardized hexane-soluble fraction of C. longa and is well known for its neuroprotective effect. Objective: In this study, we attempted to synthesize a novel chemically modified bioactive fraction from HM (NCCL) along with isolation and characterization of a novel marker compound (I). Materials and Methods: NCCL was prepared from HM. The chemical structure of the marker compound isolated from NCCL was determined from 1D/2D nuclear magnetic resonance, mass spectroscopy, and Fourier transform infrared. The compound so isolated was subjected to in silico and in vitro screenings to test its inhibitory effect on estrogen receptors. Results: Molecular docking studies revealed that the binding poses of the compound I was energetically favorable. Among NCCL and compound I taken for in vitro studies, NCCL had exhibited good anti-cancer activity over compound I against MCF-7, MDA-MB-231, DU-145, and PC-3 cells. Conclusion: This is the first study about the synthesis of a chemically modified bioactive fraction which used a standardized extract since the preparation of the HM. It may be concluded that NCCL fraction having residual components induce more cell death than compound I alone. Thus, NCCL may be used as a potent therapeutic drug.